Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)
Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...